Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merit Cudkowicz
Jeremy Shefner

Showing results (61-70 of 154) with videos related to

Pageof 16
Sort By:
The Lancet. Neurology|September 18, 2021
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trialMerit Cudkowicz, Angela Genge, Nicholas Maragakis, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 12, 2017
Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment TrialRichard Smith, Erik Pioro, Kathleen Myers, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 24, 2015
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Neta Zach, David L Ennist, Albert A Taylor, et al.
Muscle & Nerve|April 23, 2015
Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosisSabrina Paganoni, Theodore Hyman, Amy Shui, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 11, 2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment TrialRichard Smith, Erik Pioro, Kathleen Myers, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2019
IL6 receptor<sup>358</sup>Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosisMarlena Wosiski-Kuhn, Mac Robinson, Jane Strupe, et al.
Muscle & Nerve|April 5, 2013
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosisJulien Cohen-Adad, Wei Zhao, Boris Keil, et al.
NPJ Digital Medicine|December 10, 2020
Author Correction: Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysisGabriela M Stegmann, Shira Hahn, Julie Liss, et al.
NPJ Digital Medicine|October 21, 2020
Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysisGabriela M Stegmann, Shira Hahn, Julie Liss, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Pageof 16

Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
The Lancet. Neurology|September 18, 2021
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trialMerit Cudkowicz, Angela Genge, Nicholas Maragakis, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 12, 2017
Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment TrialRichard Smith, Erik Pioro, Kathleen Myers, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 24, 2015
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Neta Zach, David L Ennist, Albert A Taylor, et al.
Muscle & Nerve|April 23, 2015
Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosisSabrina Paganoni, Theodore Hyman, Amy Shui, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 11, 2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment TrialRichard Smith, Erik Pioro, Kathleen Myers, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 16, 2019
IL6 receptor<sup>358</sup>Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosisMarlena Wosiski-Kuhn, Mac Robinson, Jane Strupe, et al.
Muscle & Nerve|April 5, 2013
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosisJulien Cohen-Adad, Wei Zhao, Boris Keil, et al.
NPJ Digital Medicine|December 10, 2020
Author Correction: Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysisGabriela M Stegmann, Shira Hahn, Julie Liss, et al.
NPJ Digital Medicine|October 21, 2020
Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysisGabriela M Stegmann, Shira Hahn, Julie Liss, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Pageof 16